EUVIMED · CrossrefJournal
Pharmaceutical Statistics
ISSN 1539-1604 · Wiley
Latest articles
Evaluating Early‐Stage Oncology Clinical Trial Designs in the Era of Project Optimus: A Scoping Review
Inverse Probability of Censoring Weights for Single and Competing Events Survival Analyses With Dependent Censoring
Estimation Following Surrogate Based Selection in Multi‐Arm Drop‐The‐Losers Designs
Estimands for Randomized Discontinuation Designs in Oncology
Estimation of Treatment Effect in Clinical Trials of Continuous Endpoints With Retrieved Dropouts
A Simplified and Flexible Counterfactual Approach to Treatment Switching at a Secondary Baseline in Randomized Trials
Improving Safety Reporting: Putting the Question First and Choosing the Right Estimator for the Incidence of Treatment‐Emergent Adverse Events
Advancing Drug Development Through Bayesian Approaches: Insights Drawn From Practical Experience in Pharmaceutical R&D
A New Optimal Cut‐Points Selection Method for Diseases With Multiple Ordinal Stages and Its Confidence Interval Estimation
Bayesian Approaches in Drug Development: Interpreting the 2026 US Food and Drug Administration Draft Guidance for Optimal Dose Finding
Issue Information
A Knowledge Base of Designs and Statistical Methods for Adaptive Clinical Dose‐Finding Trials
Fiducial‐Based Statistical Intervals for Bounded Bioanalytical Data Using the Kumaraswamy Distribution
Will the Pharmaceutical Industry Need Statisticians in an AI World?
CUI ‐ MET : A Clinical Utility Index Based Analysis and Decision Framework for Dose Optimization in Multiple‐Dose, Multiple‐Outcome Randomized Trials
Optimizing Randomization Ratios in Clinical Trials With Survival Endpoints
Harmonic Fowlkes‐Mallows Index for Medical Diagnostics Tests and Optimal Cut‐Off Point Selection of Binary Diseases
Impact of Information Leakage in Platform Trials With Survival Endpoints on Type I Error Control
A Bayesian Optimal Interval Design Considering Efficacy and Toxicity in Early Phase Basket Trials
The Impact of Model Misspecification on the Individual Causal Association in Surrogate Endpoint Evaluation
Issue Information
A Dose‐Finding Design for Drug Combinations Using a Bayesian 4 Parameter Logistic Model With Penalised D‐Optimality
A Constrained Hierarchical Bayesian Model Considering Latent Biomarker Subgroups for Time‐To‐Event Endpoints in Randomized Phase II Trials
Consistency Assessment and Regional Sample Size Calculation for MRCT Under Random Effects Model
RABOTS : A Randomized Adaptive Bayesian Optimization Two‐Stage Seamless Design for Dose Optimization and Proof‐of‐Concept Evaluation
A Seamless Two‐Stage Phase I/ II Trial Design With Backfill and Joint Monitoring for Dose Optimization
Integrating Preclinical Insights for Adaptive Dose Escalation in Phase I Oncology Trials
Predictive Biomarker Graphical Approach ( PRIME ) for Precision Medicine
Phase III Probability of Success When Early Development Is Based on a Putative Surrogate Endpoint: A Vaccine Efficacy Case Study
Evolving Variants, Shifting Outcomes: Implications for Nonconcurrent Controls in Platform Trials for COVID ‐19
EUVIMED